Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Levadura comestible para inducir la tolerancia inmunológica en enfermedades autoinmunes

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20160203001
Publicado:
16/02/2016
Caducidad:
16/02/2017
Resumen:
Una universidad alemana ha desarrollado una levadura comestible inocua capaz de expresar proteínas y antígenos respectivamente. Esta levadura se utiliza para tratar enfermedades autoinmunes, como esclerosis múltiple, a través del tracto gastrointestinal. El enfoque terapéutico se basa en la inducción de tolerancia, un mecanismo clave para la prevención de la autoinmunidad. La universidad está interesada en establecer acuerdos de licencia o investigación (desarrollo clínico) con el fin de mejorar el tratamiento.



Details

Tittle:
Edible yeast to induce immunological tolerance in autoimmune diseases
Summary:
A German university developed a harmless and edible yeast that is able to express various proteins respectively antigens. This yeast addresses and finally treats several autoimmune diseases (like multiple scleroses) via the gastrointestinal tract.
The German university is offering a license agreement or research cooperation (especially a clinical development) to enhance the therapy.
Description:
Autoimmune diseases affect millions of people worldwide. They can have serious effects on life span and quality of life. Despite intensive research, the exact reasons for the onset of autoimmune diseases are still poorly understood. At present, therapies of autoimmune disorders mainly focus on the relief of symptoms rather than on the prevention of the underlying biological mechanism. Therefore, current therapeutic strategies are mostly restricted to immunomodulators or immune-suppressants.

A German university invented a novel preventive and therapeutic approach based on the induction of tolerance, which is a key mechanism for the prevention of autoimmunity. The induction of tolerance is achieved through the oral administration of antigen-expressing microorganisms.

In an animal model of multiple sclerosis, the severity and occurrence of the disease symptoms could be significantly reduced by feeding the mice with the safe fodder yeast candida utilis (torula yeast) expressing myelin oligodendrocyte glycoprotein (MOG). Thus, the oral administration of antigen-expressing candida utilis suppresses the cellular and humoral immune responses taking place in the gut-associated lymphoid tissue. Furthermore, the described treatment is considered to be safe, effective and simple.

The German university is offering a license agreement or research cooperation to enhance the therapy. Potential partners may come from pharmaceutical or possibly food industry.
Advantages and Innovations:
- Therapeutic approach based on the induction of tolerance, which is a key mechanism for the prevention of autoimmunity
- The treatment with antigen-expressing Candida utilis is safer, simpler and more effective.
Stage of Development:
Available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent application at the European Patent Office

Partner sought

Type and Role of Partner Sought:
The German university offers license agreements and the opportunity for further research co-development, especially regarding clinical development
The invented therapy is of high interest to any pharmaceutical company and possibly also the food industry.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002004 Ingeniería de proteínas
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos